JP2014528431A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528431A5
JP2014528431A5 JP2014533869A JP2014533869A JP2014528431A5 JP 2014528431 A5 JP2014528431 A5 JP 2014528431A5 JP 2014533869 A JP2014533869 A JP 2014533869A JP 2014533869 A JP2014533869 A JP 2014533869A JP 2014528431 A5 JP2014528431 A5 JP 2014528431A5
Authority
JP
Japan
Prior art keywords
sustained
coating
release pharmaceutical
water
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014533869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014528431A (ja
JP6368242B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/069541 external-priority patent/WO2013050419A1/en
Publication of JP2014528431A publication Critical patent/JP2014528431A/ja
Publication of JP2014528431A5 publication Critical patent/JP2014528431A5/ja
Application granted granted Critical
Publication of JP6368242B2 publication Critical patent/JP6368242B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014533869A 2011-10-06 2012-10-03 ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物 Expired - Fee Related JP6368242B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161544026P 2011-10-06 2011-10-06
US61/544,026 2011-10-06
PCT/EP2012/069541 WO2013050419A1 (en) 2011-10-06 2012-10-03 Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin

Publications (3)

Publication Number Publication Date
JP2014528431A JP2014528431A (ja) 2014-10-27
JP2014528431A5 true JP2014528431A5 (OSRAM) 2015-11-12
JP6368242B2 JP6368242B2 (ja) 2018-08-01

Family

ID=46968222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533869A Expired - Fee Related JP6368242B2 (ja) 2011-10-06 2012-10-03 ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物

Country Status (24)

Country Link
US (3) US20140242162A1 (OSRAM)
EP (1) EP2763663B1 (OSRAM)
JP (1) JP6368242B2 (OSRAM)
KR (1) KR101643219B1 (OSRAM)
CN (1) CN103874484B (OSRAM)
AR (1) AR088232A1 (OSRAM)
AU (1) AU2012320563B2 (OSRAM)
BR (1) BR112014007902A2 (OSRAM)
CA (1) CA2850995A1 (OSRAM)
CL (1) CL2014000844A1 (OSRAM)
CO (1) CO6930364A2 (OSRAM)
EA (1) EA025595B1 (OSRAM)
ES (1) ES2663744T3 (OSRAM)
GT (1) GT201400062A (OSRAM)
IL (1) IL231648A0 (OSRAM)
MA (1) MA35513B1 (OSRAM)
MX (1) MX2014004166A (OSRAM)
PE (1) PE20141649A1 (OSRAM)
PH (1) PH12014500746A1 (OSRAM)
SG (1) SG11201400730VA (OSRAM)
TN (1) TN2014000114A1 (OSRAM)
TW (1) TWI475993B (OSRAM)
WO (1) WO2013050419A1 (OSRAM)
ZA (1) ZA201401961B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201503912A (zh) * 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
JP6678676B2 (ja) 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
MX2017010872A (es) 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
CN107847491A (zh) 2015-05-20 2018-03-27 诺华公司 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
JP6762158B2 (ja) * 2015-07-28 2020-09-30 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
US10383860B2 (en) 2015-07-28 2019-08-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
JP6793652B2 (ja) * 2015-09-03 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
JP6854639B2 (ja) * 2016-01-06 2021-04-07 日本化薬株式会社 ラパマイシン誘導体を含有する医薬組成物及びその製造方法
US12485129B2 (en) 2016-08-29 2025-12-02 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CN110177543A (zh) 2016-08-29 2019-08-27 凯诺比生长公司 包含纯化大麻素的水溶性组合物
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
WO2018142356A1 (en) * 2017-02-06 2018-08-09 Intas Pharmaceuticals Ltd. Pharmaceutical composition of everolimus
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
EP4125913A4 (en) * 2020-03-30 2023-08-23 IGIA Pharmaceuticals, Inc. PEDIATRIC TYROSINE KINASE INHIBITOR FORMULATION
WO2022219652A1 (en) * 2021-04-17 2022-10-20 Bdr Pharmaceuticals International Private Limited Novel sublingual pharmaceutical formulations for everolimus
KR102336007B1 (ko) * 2021-06-23 2021-12-07 주식회사 진성이앤지 콘크리트용 우레탄계 방수·방식 도막재 및 이를 이용한 방수·방식 도장 공법
WO2023044024A1 (en) * 2021-09-17 2023-03-23 Novelstar Pharmaceuticals Inc. Novel ph dependent coating drug delivery system

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
EP1902708A1 (de) * 2006-09-25 2008-03-26 Losan Pharma GmbH Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
EP2365802B1 (en) * 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
CN101862297B (zh) * 2009-04-14 2012-07-25 上海医药工业研究院 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法

Similar Documents

Publication Publication Date Title
JP2014528431A5 (OSRAM)
JP4656815B2 (ja) 一日に一回のオキシコドン製剤
JP5937068B2 (ja) 転用防止微粒剤および微小錠剤
JP6325148B2 (ja) 注意欠陥障害の処置のための方法および組成物
JP2014505736A5 (OSRAM)
ES2582453T3 (es) Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada
JP5592902B2 (ja) 治療薬の徐放性組成物
JP2013199488A5 (OSRAM)
EA200900270A1 (ru) Системы регулируемого высвобождения и способ их приготовления
CA2488868A1 (en) Controlled release formulation of lamotrigine
JP2018517735A5 (OSRAM)
JP2006514988A5 (OSRAM)
JP2013530138A (ja) アルコール耐性経口医薬形態
US20210220281A1 (en) Oral pharmaceutical compositions of mesalazine
WO2015193788A1 (en) Formulation for oral administration containing mesalazine
JP2017536401A5 (OSRAM)
JP2017532363A5 (OSRAM)
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
JP2014208655A5 (OSRAM)
HRP20161340T1 (hr) Formulacije darunavira
JP2010518002A5 (OSRAM)
CA2967647A1 (en) Pharmaceutical bead formulations comprising dimethyl fumarate
RU2014132940A (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
US20110244050A1 (en) Pulsed-release sildenafil composition and method for preparing said composition
JP2019513801A5 (OSRAM)